Agoracom Blog Home

Posts Tagged ‘Hemp’

« Older Entries
Newer Entries »

PRIMO Nutraceuticals $PRMO.ca – #CBD Nutraceuticals Market Demand, Supply, Growth Factors, Latest Rising Trend & Forecast to 2027 $CROP.ca $VP.ca NF.ca $MCOA

Posted by AGORACOM-JC at 12:53 PM on Tuesday, May 5th, 2020

SPONSOR:  PRIMO NUTRACEUTICALS INC. (CSE: PRMO) (OTC: BUGVF) (FSE: 8BV) (DEU: 8BV) (MUN: 8BV) (STU: 8BV) provides strategic capital to the thriving cannabis cultivation sector through ownership and development of commercial real estate properties. The company also offers fully built out turnkey facilities equipped with state-of-the-art growing infrastructure to cannabis growers and processors. Click here for more info.

CBD Nutraceuticals Market Demand, Supply, Growth Factors, Latest Rising Trend & Forecast to 2027

The Covid-19 (coronavirus) pandemic is impacting society and the overall economy across the world. The impact of this pandemic is growing day by day as well as affecting the supply chain. The COVID-19 crisis is creating uncertainty in the stock market, massive slowing of supply chain, falling business confidence, and increasing panic among the customer segments. The overall effect of the pandemic is impacting the production process of several industries including Life Science, and many more. Trade barriers are further restraining the demand- supply outlook.

As government of different regions have already announced total lockdown and temporarily shutdown of industries, the overall production process being adversely affected; thus, hinder the overall CBD Nutraceuticals Market globally. This report on ‘CBD Nutraceuticals Market’ provides the analysis on impact on Covid-19 on various business segments and country markets. The report also showcase market trends and forecast to 2027, factoring the impact of Covid -19 Situation.

A nutraceutical is a pharmaceutical alternative that claims physiological benefits. Nutraceutical product is a food or fortified food product that not only supplements the diet but also assists in treating or preventing disease (apart from anemia), so it provides medical benefits. A naturally-occurring compound found in plants, cannabidiol (CBD), belongs to a family of compounds called cannabinoids. Examples of nutraceuticals are natural foods, including antioxidants, dietary supplements, fortified dairy products, and citrus fruits, and vitamins, minerals, herbals, milk, and cereals.

The CBD nutraceuticals market is anticipated to grow due to the products as they are more convenient and travel-friendly. However, the presence of alternatives like the herbal nutraceuticals, such as echinacea, and turmeric that have ruled the global nutraceuticals space for a long period, is restraining the market growth. Moreover, the growing demand for hemp protein among athletes, bodybuilders, and the vegan population is expected to drive the market for cannabidiol (CBD) nutraceuticals over the forecast period.

Key Players Influencing the Market:

1. Bluebird Botanicals
2. CV Sciences, Inc.
3. Elixinol LLC
4. Endoca BV
5. Foria Wellness
6. Garden of Life
7. Green Roads
8. Isodiol
9. Medical Marijuana, Inc.
10. MEDTERRA

Market Segmentation:

The CBD nutraceuticals market is segmented on the basis of product type, and sales channel. Based on product type the market is segmented as CBD tinctures, capsules & softgels, CBD gummies, others. On the basis of sales channel the market is categorized as retail stores and online pharmacies.

Source: https://coleofduty.com/news/2020/05/05/cbd-nutraceuticals-market-demand-supply-growth-factors-latest-rising-trend-forecast-to-2027/

Tags: , , , , , ,
Posted in PRIMO Nutraceuticals Inc. | Comments Off on PRIMO Nutraceuticals $PRMO.ca – #CBD Nutraceuticals Market Demand, Supply, Growth Factors, Latest Rising Trend & Forecast to 2027 $CROP.ca $VP.ca NF.ca $MCOA

Mota Ventures $MOTA.ca Acquires A Record 17,996 New Customers in April $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 11:05 AM on Tuesday, May 5th, 2020
https://s3.amazonaws.com/s3.agoracom.com/public/companies/logos/564664/hub/MOTA_Large.png

VANCOUVER, BC / ACCESSWIRE / May 5, 2020 / Mota Ventures Corp. (CSE:MOTA)(FSE:1WZ1)(OTC PINK:PEMTF) (the “Company“) is excited to announce for the month of April, it acquired 17,996 new customers. This represents an increase of 48% compared to April 2019. In April, the Company also experienced strong demand from customers enrolling in a subscription, totaling of 14,091 new subscribers during the month. This represents a new subscriber increase of 78% compared to April 2019.

The Company’s Natures Exclusive brand offers a CBD hemp-oil formulation intended to provide users with the therapeutic benefits that hemp may offer. The hemp oil used in the products is derived from hemp grown and cultivated in the United States. The extraction process is designed to maintain all the beneficial qualities that hemp may offer. Natures Exclusive offers a range of products, which include CBD oil drops, CBD gummies, CBD pain relief cream, CDB skin serum and CBD coffee.

“We continue to see strong consumer demand for our entire range due to our concentrated customer acquisition efforts and by providing compelling products our customers are asking for. Our April new customer acquisition and subscription numbers are continued evidence of the strength of the business. Additionally, I am excited about our recent launch of a CBD hand sanitizer product and anticipate we will see very strong sales through this current quarter,” stated Ryan Hoggan, CEO of the Company.

The Company also announces that it has granted 7,995,000 incentive stock options to certain directors, officers and consultants of the Company. The options vest immediately, and are exercisable at a price of $0.30 for a period of 60 months. The options are governed by the terms of the Company’s incentive stock option plan, and the policies of the Canadian Securities Exchange.

About Mota Ventures Corp.

Mota Ventures is an established eCommerce, direct to consumer provider of a wide range of CBD products in the United States and Europe. In the United States, the Company sells a CBD hemp-oil formulation derived from hemp grown and formulated in the US through its Nature’s Exclusive brand. Within Europe, its Sativida brand of award winning 100% organic CBD oils and cosmetics are sold throughout Spain, Portugal, Austria, Germany, France, and the United Kingdom. Mota Ventures is also seeking to acquire additional revenue producing CBD brands and operations in both Europe and North America, with the goal of establishing an international distribution network for CBD products. Low cost production, coupled with international, direct to customer, sales channels will provide the foundation for the success of Mota Ventures.

ON BEHALF OF THE BOARD OF DIRECTORS

MOTA VENTURES CORP.

Ryan Hoggan

Chief Executive Officer

For further information, readers are encouraged to contact Joel Shacker, President at +604.423.4733 or by email at [email protected] or www.motaventuresco.com

Tags: , , , , , , , , ,
Posted in All Recent Posts, Mota Ventures Corp. | Comments Off on Mota Ventures $MOTA.ca Acquires A Record 17,996 New Customers in April $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Spyder $SPRD.ca Announces Licence to Open #Cannabis Retail Store in Calgary, Alberta $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 8:42 AM on Tuesday, May 5th, 2020
  • Received a licence from the Alberta Gaming, Liquor and Cannabis commission to open its first store in Calgary, Alberta
  • It is anticipated that the store, located at 104-58th Ave, SE, suite 140 Calgary, Alberta and operate as SPDR Cannabis,
  • Will open in the month of June.

Vaughan, Ontario–(May 5, 2020) – Spyder Cannabis Inc. (TSXV: SPDR) (“Spyder” or the “Company“) and its wholly-owned associated applicants, The Green Spyder Inc. and Spyder Cannabis Subco Inc., is pleased to announce that it has received a licence from the Alberta Gaming, Liquor and Cannabis commission (the “AGLC”) to open its first store in Calgary, Alberta. It is anticipated that the store, located at 104-58th Ave, SE, suite 140 Calgary, Alberta and operate as SPDR Cannabis, will open in the month of June. It will offer a full assortment of cannabis products from licenced producers.

“We are excited to open our first licenced cannabis store in Calgary, Alberta, a province which led the way in the rollout of the Canadian cannabis market. The store is ideally located in a busy hub of commercial retail establishments”, said Daniel Pelchovitz Spyder’s President & CEO. “We very much look forward to bringing the Spyder brand and retail experience focus to Calgary”.

About Spyder Cannabis Inc.

Spyder is a Cannabis, Vape and CBD retailer that operates in jurisdictions where the products are federally legal in both Canada and the United States. The Company, through its subsidiaries, is a retailer involved in the development of three retail business units. The first is the sale of Cannabis products, the second is the sale of CBD in the United States only, the third is the sale of smoking cessation products in Ontario.

Cautionary Statements

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release includes statements containing certain “forward-looking information” within the meaning of applicable securities laws (“forward-looking statements”). Forward- looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur.

FOR ADDITIONAL INFORMATION, PLEASE CONTACT:

For more information, please contact:

Spyder Cannabis Inc.
Dan Pelchovitz
President & Chief Executive Officer
Telephone: 1.888.504.7737
Email: [email protected]

Tags: , , , , ,
Posted in Spyder Cannabis Inc. | Comments Off on Spyder $SPRD.ca Announces Licence to Open #Cannabis Retail Store in Calgary, Alberta $CGC $ACB $APH $CRON.ca $OGI.ca

Empower Clinics $CBDT.ca Announces April 2020 Patient Growth of 871% and Orders Additional Supplies for #Covid19 Testing $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 8:39 AM on Tuesday, May 5th, 2020
  • EMPOWER SEES SUBSTANTIAL YEAR-OVER-YEAR PATIENT GROWTH WHILE ROLLING OUT ADDITIONAL SERVICES AND CONTINUES TO PURCHASE SUPPLIES AND EQUIPMENT TO SUPPORT EXPANSION OF COVID-19 ANTIBODY TESTING
  • Patient visits in corporate clinics increased by 871% in April 2020 versus the same period in 2019,
  • Total patient visits of 2,212 in April 2020 compared to 254 in April 2019.

VANCOUVER, BC / May 5, 2020 / EMPOWER CLINICS INC. (CSE:CBDT)(OTCQB:EPWCF)(Frankfurt:8EC) (“Empower” or the “Company“), a vertically integrated life sciences company, is pleased to announce that patient visits in corporate clinics increased by 871% in April 2020 versus the same period in 2019, with total patient visits of 2,212 in April 2020 compared to 254 in April 2019.

The Company is booking new physician appointments for immune boosting services that are leading to naturopathic product sales and the ordering of specialized tests. In addition, the Company has increased orders of Personal Protective Equipment (PPE) and equipment such as stainless-steel tables, portable air conditioning units, tents and medical supplies to support staff and patients as part of a medical testing protocol in the United States.

The Company has also been identified by Amazon Business as needing access to critical supplies and as such, the Company has been awarded access to the Amazon COVID-19 SUPPLIES portal, which provides access to essential products for organizations participating in the fight against Coronavirus.

“The performance results from April are truly outstanding and given the operational changes the team have made as a result of Coronavirus, I am immensely proud of their efforts” said Steven McAuley, Chairman & CEO of Empower. “We are starting to see strong diversification in the revenue model for our clinics that will help us grow not only patient count, but revenue per patient, total revenue and perhaps more importantly, create revenue diversity to reduce concentration risk for the business model.”

ABOUT EMPOWER

Empower is a vertically integrated health & wellness brand with a network of corporate and franchised health & wellness clinics in the U.S. The Company is building its first hemp-derived CBD extraction facility and produces its proprietary line of cannabidiol (CBD) based products. The Company is a leading multi-state operator of a network of physician-staffed wellness clinics, focused on helping patients improve and protect their health, through innovative physician recommended treatment options. The Company has commenced activity on how to connect its significant data, to the potential of the efficacy of alternative treatment options related to hemp-derived cannabidiol (CBD) therapies, psilocybin and other psychedelic plant-based treatment options. The Company now offers COVID-19 testing options in the United States and physician-based consultations, to address COVID-19 concerns.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

CONTACTS:

Investors: Steven McAuley
CEO
[email protected]
604-789-2146

Investors: Dustin Klein
SVP, Business Development
[email protected]
720-352-1398

For French inquiries: Remy Scalabrini, Maricom Inc., E: [email protected], T: (888) 585-MARI

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws.All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include statements regarding: the Company’s expected timing of filing of its Annual Filings, the Company’s intention to create psilocybin and psychedelics divisions, that market research on advancements in psilocybin and psychedelics in North America and globally will create greater shareholder value, the Company’s intention to open a hemp-based CBD extraction facility, the expected benefits to the Company and its shareholders as a result of the proposed acquisitions and partnerships; the effectiveness of the extraction technology; the expected benefits for Empower’s patient base and customers; the benefits of CBD based products; the effect of the approval of the Farm Bill; the growth of the Company’s patient list and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2019 and beyond; the ability of the Company to complete or execute phases One, Two, Three or Four as noted above, and Psychedelic substances remain illegal in most countries, so please reference your local laws in relation to medical or recreational use. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including; that the Company may not open a hemp-based CBD extraction facility; that legislative changes may have an adverse effect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed acquisitions and partnerships; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

SOURCE: Empower Clinics Inc.

Tags: , , , ,
Posted in Empower Clinics Inc. | Comments Off on Empower Clinics $CBDT.ca Announces April 2020 Patient Growth of 871% and Orders Additional Supplies for #Covid19 Testing $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca

Primo Nutraceuticals $PRMO.ca Signs Definitive Agreement with Celebrity Brand Beauty Kitchen $CROP.ca $VP.ca NF.ca $MCOA

Posted by AGORACOM-JC at 8:47 AM on Monday, May 4th, 2020
  • Company has signed a definitive agreement to complete the “Transaction”
  • Beauty Kitchen is a company that manufactures fresh handmade beauty care, personal care and cosmetic products
  • born from the hugely popular Beauty Kitchen YouTube Series, with do-it-yourself beauty recipes made with common kitchen household ingredients

VANCOUVER, British Columbia, May 04, 2020 — PRIMO NUTRACEUTICALS INC. (CSE: PRMO) (OTC: BUGVF) (FSE: 8BV) (DEU: 8BV) (MUN: 8BV) (STU: 8BV) (“Primo” or the “Company”) is pleased to announce that further to its letter of intent (“LOI”) with Heather Marianna LLC (“Beauty Kitchen”), announced in the Company’s news release dated March 31st, 2020, the Company has signed a definitive agreement to complete the “Transaction”

Beauty Kitchen is a company that manufactures fresh handmade beauty care, personal care and cosmetic products. It was born from the hugely popular Beauty Kitchen YouTube Series, with do-it-yourself beauty recipes made with common kitchen household ingredients. Due to their huge success and major celebrity following, the company and Founder Heather Marianna decided to expand into the Canadian market under the brand name Marianna Naturals Corp.

Marianna Naturals Corp. has been granted the exclusive Canadian distribution rights to its CBD infused and non-CBD infused products in handmade beauty care, personal care and cosmetic products. The signing of the definitive agreement gives Primo 25% ownership in Marianna Naturals Corp.

TERMS OF THE TRANSACTION

Under the terms of the transaction with Marianna Naturals Corp., Primo will provide Marianna Naturals Corp. with capital market advisory services, business development and strategic management, administrative and organizational services(the “Services”) as well as assistance in becoming a “reporting issuer” in Canada to facilitate their objective to list their shares on the CSE (“CSE”).  

It is proposed that the Transaction be carried out within a Statutory Plan of Arrangement pursuant to the Business Corporations Act of (British Columbia) under the “reorganization exemption” under the B.C. Securities Act.

The Plan of Arrangement will be subject to the approval of Primo’s shareholders which Primo intends to seek at a special meeting of shareholders (the “Shareholders’ Meeting“), for which the date has not yet been determined. The Transaction may be subject to the rules of the CSE and approved by a Court Order of the British Columbia Supreme Court.

Under the terms of the Plan of Arrangement, Primo shareholders would receive new common shares of Marianna Naturals Corp. the number of which has not yet been determined. There will be no change in Primo’s shareholders’ holdings as a result of the Plan of Arrangement.

Andy Jagpal, President Comments:

”I would like to take the time to welcome Joel DeBellefeuille, the CEO of Marianna Naturals Corp.  Joel brings an array of knowledge to our Company and we are very excited to work with both himself and his team.”

Joel DeBellefeuille, Director & CEO of Marianna Naturals Corp. Comments:

“Exciting times are definitely ahead, and I couldn’t be happier with the current direction Primo is taking. With this newly formed partnership, Primo can hit the market with over 100 different beauty products (creams, lotions & topicals, eye gels, soap bars, shampoos, face serums and hand sanitizers to name a few), all of which can be infused with CBD. This is a major advantage over some of the big LPs out there that are spending big money on R&D and formulation. Quality assurance, product development, recipes, ingredients, SOP’s (Standard Operating Procedures) and MSDS (Material Safety Data Sheets) are already in place with Marianna Naturals Corp. Primo is ready to sell and or take Private Label requests right now. The only thing that Primo would have to do is to file a request for an NPN (Natural Product Number) for each of these products with Health Canada. This is a huge milestone for Primo and a major recipe for success and I appreciate the team bringing me on board. I look forward to the future of both companies.”

About Marianna Naturals Corp.

Marianna Naturals Corp. and Beauty Kitchen manufactures fresh handmade CBD & non-CBD beauty care, personal care, and cosmetics products, which was born from the hugely popular Beauty Kitchen YouTube series. The founder, Heather Marianna, a bubbly social media personality, translated her passion for looking and feeling her absolute best into the development of her all-natural beauty and skincare product line. Beauty Kitchen’s founder and CEO, Heather Marianna, skyrocketed in popularity with the launch of her Beauty Kitchen YouTube series in 2012 where she showcased simple, do-it-yourself beauty recipes made with common kitchen household ingredients. The series generated a powerful following of more than 4 million viewers. Beauty Kitchen is regularly featured in: Forbes, The Source, MTV, Bravo, The New York Post, People, Flipsnack, Vegas, Star Magazine, Radar Online and many more media outlets with a large following of celebrities who use their products which include; Sean “Puffy” Combs, Christina Milian, David Arquette, George Lopez, Larissa Lima, Shark Tank’s Barbara Corcoran, Candace Cameron, Jen Harley, Lou Ferrigno, The Real Housewives of Beverly Hills and others. For more information visit: www.beautykitchenonline.com or www.marianna.ca 

About Primo Nutraceuticals 

Primo Nutraceuticals Inc. (“Primo” or the “Company”) provides strategic capital to the thriving cannabis cultivation sector through ownership and development of commercial real estate and farm friendly properties. Primo is dedicated to funding the rapid growth in production, processing, retail and branding of cannabis and cannabis related products in Canada and the United States. Primo has invested in several brands and is pursuing partnerships with retailers and distribution companies in Canada and the United States. Primo’s management is in the process of building a corporate road map to further vertically integrate the Company, specifically by way of “Primo” branded retail outlets – offering “Thrive,” “Primo,” and a selection of curated partner brands. The Company possesses proprietary formulas for cannabis edibles, topical, and tinctures. Primo is focused on building a strong presence in the hemp industry with the objective of extracting and selling cannabinoids (CBD) products in both Canada and the United States.

On behalf of the Board of Directors

PRIMO NUTRACEUTICALS INC.

“Andy Jagpal”

President and Director

For further information, please contact Zoltan, IR Representative at: 604-722-0305, or; [email protected]

To learn more about what this news means to the shareholders visit:

Join the Telegram. t.me/PrimoNutraceuticals

Shop:www.primoceuticals.com

www.twitter.com/prmonutra

www.thrivecbd.org

Corporate:www.primonutraceuticals.com

FORWARD LOOKING STATEMENTS: This news release contains certain forward-looking statements within the meaning of Canadian securities laws. Forward-looking statements are based on the expectations and opinions of the Company’s management on the date the statements are made. The assumptions used in the preparation of such statements, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise. No regulatory authority has approved or disapproved the information contained in this news release.

Tags: , , , , , ,
Posted in Featured, PRIMO Nutraceuticals Inc. | Comments Off on Primo Nutraceuticals $PRMO.ca Signs Definitive Agreement with Celebrity Brand Beauty Kitchen $CROP.ca $VP.ca NF.ca $MCOA

Israel Researchers Launch Clinical Trials To Test #CBD As #COVID19 Treatment Supplement – SPONSOR: Hollister Biosciences $HOLL.ca $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca $FAF.ca

Posted by AGORACOM-JC at 9:00 PM on Sunday, May 3rd, 2020

SPONSOR: Hollister Biosciences Inc. (HOLL:CSE) A vertically integrated cannabis company with products in 220 California dispensaries and joint ventures, licensing agreement & partnerships with global brands. The company recently closed $20 MILLION deal with Venom Extracts adding $CDN 16.4 million in revenue and $CDN 2.48 million in EBITDA. Learn More

Israel Researchers Launch Clinical Trials To Test CBD As COVID-19 Treatment Supplement

Israeli researchers have launched three clinical trials that utilize CBD’s anti-inflammatory properties as potential COVID-19 treatment.

  • Israeli scientists have launched clinical trials into whether cannabis can play an effective role in stopping or slowing the coronavirus
  • Though lung health experts have warned smoking marijuana could exacerbate COVID-19 and its spread, Israeli scientists will study cannabidiol (CBD) alongside existing treatment options as a possible solution

By: The Fresh Toast , Benzinga Contributor

Israeli scientists have launched clinical trials into whether cannabis can play an effective role in stopping or slowing the coronavirus. Though lung health experts have warned smoking marijuana could exacerbate COVID-19 and its spread, Israeli scientists will study cannabidiol (CBD) alongside existing treatment options as a possible solution.

Last week, InnoCan Pharma announced a collaboration with Tel Aviv University to instill CBD medicine through exosomes — or the small cell structures created when stem cells multiply. The unconventional method will utilize the exosomes as “homing missiles,” as they can uniquely target cell organs damaged by COVID-19. Researchers then believe CBD’s anti-inflammatory properties will repair the damaged cells through a synergistic effect. As COVID-19 attacks the respiratory system, scientists will have patients receive CBD-enriched exosomes through an inhalation device. Previous studies have shown CBD can help regulate the body’s immune system and reduce inflammation throughout the body.

A second clinical trial will occur over the coming weeks and includes 10 Covid-19 patients currently undergoing treatment in Israel’s Rabin Medical Center. Doctors will combine traditional steroids and CBD, with the belief CBD will enhance the therapeutic potential of the steroids. The trial, conducted by Stero Biotechs in collaboration with Mor Research Application, already has plans to expand treatment to 40 additional patients should it prove successful.

“We estimate that our CBD-based treatment can enhance the current treatment of those patients who are in life-threatening conditions,” Stero Biotechs founder and CEO David Bassa said in a statement. “Hospitalized COVID-19 patients are mostly being treated with steroids and our study is planned to demonstrate the benefit of a combined solution with Steroid treatments. We are hopeful that this study will lead to faster benefit for the growing number of COVID-19 patients in Israel and around the world.”

A third study, launched by Tel Aviv’s Ichilov Medical Center, will investigate whether CBD’s anti-inflammatory properties could lower respiratory symptoms experienced in moderate COVID-19 patients.

Canadian researchers have also announced intentions to study what role cannabis can play in slowing COVID-19. They also believe marijuana’s anti-inflammatory properties could provide a crucial role in potential treatment.

Source: https://www.benzinga.com/markets/cannabis/20/04/15877325/israel-researchers-launch-clinical-trials-to-test-cbd-as-covid-19-treatment-supplement

Tags: , , , , , ,
Posted in Hollister Biosciences | Comments Off on Israel Researchers Launch Clinical Trials To Test #CBD As #COVID19 Treatment Supplement – SPONSOR: Hollister Biosciences $HOLL.ca $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca $FAF.ca

Empower Clinics $CBDT.ca Confirms Phase One and Phase Two Corona Virus #COVID19 Antibody Testing is Underway and Provides Updates on Timing of Fourth Quarter and Annual Financial Results $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 3:55 PM on Thursday, April 30th, 2020
  • Empower confirms it has commenced COVID-19 antibody testing in clinics under the phase one and phase two rollout plans,
  • Received first Rapid COVID-19 test kits and places additional purchases of Rapid COVID-19 test kits

VANCOUVER, BC / April 29, 2020 / EMPOWER CLINICS INC. (CSE:CBDT)(OTCQB:EPWCF)(Frankfurt:8EC) (“Empower” or the “Company“), a vertically integrated life sciences company, is pleased to announce it is actively testing patients using COVID-19 antibody testing under its phase one and phase two rollout plans in its Sun Valley Health clinics in Phoenix, AZ. The Company has also received its first Rapid COVID-19 antibody test kits and has purchased additional Rapid test kits to start meeting testing demand. The Company also provides an update on the timing of the release of its financial results and associated filings for the fourth quarter and fiscal year ended December 31, 2019.

The Company is utilizing the temporary relief exemption provided by the Ontario Securities Commission under Ontario Instrument 51-502 – Temporary Exemption from Certain Corporate Finance Requirements (the “Instrument“), which provides a 45-day extension for periodic filings, including annual audited financial statements, as required by section 4.1(2) of National Instrument 51-102 – Continuous Disclosure Obligations, and related management’s discussion and analysis and CEO and CFO certifications (collectively, the “Annual Filings“), for the year ended December 31, 2019.

In accordance with the Instrument, the Company intends to file its Annual Filings no later than the extended deadline, as permitted under the Instrument, of June 15, 2020.

Until the Company has filed the Annual Filings, the Company confirms that its management and other insiders are subject to a trading blackout that reflects the principles in section 9 of National Policy 11-207 Failure-to-File Cease Trade Orders and Revocations in Multiple Jurisdictions. The Company further confirms that, other than as disclosed in this news release or other news releases or material change reports filed by the Company since November 14, 2019, being the date of filing of the Company’s unaudited interim financial statements and related filings for the period ended September 30, 2019, there have been no undisclosed material business developments with respect to the Company.

“The Company’s four-phase national COVID-19 testing program utilizing Rapid COVID-19 test kits is underway in the United States and our first patients are expecting test results starting today,” said Steven McAuley, Chairman & CEO of Empower. “The operational processes we have established to manage the patient experience are proving stable and effective, as is the technology workflow that registers a patient, books an appointment and collects payment on the Sun Valley Health website.”

Phase One – Testing in clinics in Arizona, utilizing a patient blood draw by clinic phlebotomists, then samples are sent to our laboratory test partner for analysis, with test results expected within 48 hours. This program is now active and appointment rates are expanding rapidly.

Phase Two – Offering a Rapid COVID-19 antibody test with results in 1-15 minutes. The service will be offered in-clinics using a drive-up service, conducted by Company clinic staff. In addition, an outbound door-step service, to support a variety of consumer, patient and community needs will be offered using certified mobile technicians. The online portal will be open to book appointments commencing May 1, 2020.

Phase Three – Business Employee Testing (BET) programs, offering Rapid COVID-19 testing to businesses on a one-time basis, repeat basis and/or subscription basis, to assist businesses to get back to work safely, will be offered. The Company anticipates phase three services will commence in May 2020.

Phase Four – U.S. nationwide roll-out, offering all phases of Company services, that can be accessed online at Company websites and call centers, to purchase Rapid COVID-19 test kits. The Company anticipates phase four services to commence in Q3 2020.

ABOUT EMPOWER

Empower is a vertically integrated health & wellness brand with a network of corporate and franchised health & wellness clinics in the U.S. The Company is building its first hemp-derived CBD extraction facility and produces its proprietary line of cannabidiol (CBD) based products. The Company is a leading multi-state operator of a network of physician-staffed wellness clinics, focused on helping patients improve and protect their health, through innovative physician recommended treatment options. The Company has commenced activity on how to connect its significant data, to the potential of the efficacy of alternative treatment options related to hemp-derived cannabidiol (CBD) therapies, psilocybin and other psychedelic plant-based treatment options. The Company now offers COVID-19 testing options in the United States and physician-based consultations, to address COVID-19 concerns.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

CONTACTS:

Investors: Steven McAuley
CEO
[email protected]
604-789-2146

Investors: Dustin Klein
SVP, Business Development
720-352-1398
[email protected]

For French inquiries: Remy Scalabrini, Maricom Inc., E: [email protected], T: (888) 585-MARI

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include statements regarding: the Company’s expected timing of filing of its Annual Filings, the Company’s intention to create psilocybin and psychedelics divisions, that market research on advancements in psilocybin and psychedelics in North America and globally will create greater shareholder value, the Company’s intention to open a hemp-based CBD extraction facility, the expected benefits to the Company and its shareholders as a result of the proposed acquisitions and partnerships; the effectiveness of the extraction technology; the expected benefits for Empower’s patient base and customers; the benefits of CBD based products; the effect of the approval of the Farm Bill; the growth of the Company’s patient list and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2019 and beyond; the ability of the Company to complete or execute phases One, Two, Three or Four as noted above, and Psychedelic substances remain illegal in most countries, so please reference your local laws in relation to medical or recreational use. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including; that the Company may not open a hemp-based CBD extraction facility; that legislative changes may have an adverse effect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed acquisitions and partnerships; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

Tags: , , , , ,
Posted in All Recent Posts, Empower Clinics Inc. | Comments Off on Empower Clinics $CBDT.ca Confirms Phase One and Phase Two Corona Virus #COVID19 Antibody Testing is Underway and Provides Updates on Timing of Fourth Quarter and Annual Financial Results $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca

Hollister Biosciences $HOLL.ca Closes Acquisition of AlphaMind Brands Inc. $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca $FAF.ca

Posted by AGORACOM-JC at 8:15 AM on Thursday, April 30th, 2020
  • Company has now closed its acquisition of AlphaMind Brands Inc., a growth stage company, that is developing a portfolio of certified legal mushroom based natural health products
  • Hollister will not be assuming any long-term debt; no new control position will be created and there is no change in management or the Board of Directors of Hollister in connection with the Transaction

VANCOUVER, April 30, 2020 - Hollister Biosciences Inc. (CSE: HOLL, FRANKFURT: HOB, OTC: HSTRF) (the “Company” or “Hollister“) – a diversified cannabis branding company with products in over 220 dispensaries throughout California, is pleased to announce that further to the signing of the definitive agreement, as amended (the “SEA“), the Company has now closed its acquisition of AlphaMind Brands Inc. (“AlphaMind“), a growth stage company, that is developing a portfolio of certified legal mushroom based natural health products (the “Transaction“).

“We are very pleased to close our acquisition of AlphaMind”, shared Carl Saling, Founder and CEO of Hollister.  “It is our continual objective to broaden our product scope and Alphamind, with its experienced management team, is a perfect foothold for us in the fast-growing market for medicinal mushrooms and complements our existing cannabis and hemp-based product offering.  We are excited to bring another promising brand under the Hollister umbrella, especially in such a fast growing and exciting sector.”

“We are very pleased to have closed this transaction”, shared Dr. Nikos C. Apostolopoulos, Chief Product & Research Officer of Alphamind Brands.  “We are looking forward to working with Hollister to build out our medicinal mushroom based product line and conducting further R&D to develop an exciting IP portfolio surrounding psilocybin based pharmaceutical treatments.”

Key Terms of The Transaction

Pursuant to the terms of the SEA, the Company has acquired AlphaMind for consideration of CDN$1,200,000 which is being satisfied by the issuance of 4,200,000 Hollister common shares (the “Payment Shares“) on the Closing Date pro rata to the shareholders of AlphaMind and an additional 1,800,000 common shares (the “Earn-Out Shares“) to be issued pro rata to the former shareholders of AlphaMind on the earlier of (i) AlphaMind meeting certain milestones (detailed below) or (ii) December 31st, 2021.

  • The Payment Shares and the Earn-Out Shares will be issued at a deemed value of $0.20 per share;
  • The Payment Shares are subject to certain voluntary hold periods as follows: 331/3% until May 30th, 2020; an additional 331/3% until June 30th, 2020; and the remaining 331/3% until August 30th, 2020;
  • The Earn-Out Shares will be issued on the earlier of (i) December 31st, 2020, or (ii) upon AlphaMind’s first production run or its first sales of product.

Hollister will not be assuming any long-term debt; no new control position will be created and there is no change in management or the Board of Directors of Hollister in connection with the Transaction.

About AlphaMind Brands Inc.

Alphamind Brands is a Canada and US based growth stage company, that is developing a portfolio of certified legal mushroom based natural health products. It is also actively conducting R&D initiatives, led by Dr. Nikos C. Apostolopoulos, who is exploring psilocybin based pharmaceutical treatments.  The company’s “ready to ship” product SKU’s include Cordyceps, Lion’s Mane, Shiitake, Oyster and Reishi Mushroom based: liquid tinctures, concentrated mushroom powder(s), teas, and chocolate. 

About Hollister Biosciences Inc.

Hollister Biosciences Inc. is a multi-state cannabis company with a vision to be the sought-after premium brand portfolio of innovative, high-quality cannabis & hemp products. Hollister uses a high margin model, controlling the whole process from manufacture to sales to distribution or seed to shelf. Products from Hollister Biosciences Inc. include HashBone, the brand’s premier artisanal hash-infused pre-roll, along with concentrates (shatter, budder, crumble), distillates, solvent-free bubble hash, pre-packaged flower, pre-rolls, tinctures, vape products, and full-spectrum high CBD pet tinctures. Hollister Cannabis Co. additionally offers white-labeling manufacturing of cannabis products.  Our wholly-owned California subsidiary Hollister Cannabis Co is the 1st state and locally licensed cannabis company in the city of Hollister, CA birthplace of the “American Biker”.

Website: www.hollistercannabisco.com

ON BEHALF OF THE BOARD

“Carl Saling”

CEO and Director

The CSE does not accept responsibility for the adequacy or accuracy of this release.

The CSE has not in any way passed upon the merits of the Transaction and has neither approved nor disapproved the contents of this press release.

The securities to be issued in connection with the Transaction have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “1933 Act“), or under any state securities laws, and may not be offered or sold, directly or indirectly, or delivered within the United States or to, or for the account or benefit of, U.S. persons (as defined in Regulation S under the 1933 Act) absent registration or an applicable exemption from the registration requirements. This news release does not constitute an offer to sell or a solicitation to buy such securities in the United States.

This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.

View original content to download multimedia:http://www.prnewswire.com/news-releases/hollister-biosciences-closes-acquisition-of-alphamind-brands-inc-301049911.html

Tags: , , , , , ,
Posted in Hollister Biosciences | Comments Off on Hollister Biosciences $HOLL.ca Closes Acquisition of AlphaMind Brands Inc. $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca $FAF.ca

Discovering the Benefits of CBD Oil SPONSOR: Mota Ventures $MOTA.ca $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 2:25 PM on Wednesday, April 29th, 2020

SPONSOR: Mota is seeking to become a vertically integrated global CBD brand. Mota is creating sales channels and a distribution network internationally through the acquisition of the Sativida and First Class CBD brands. Low cost production, coupled with international, direct to customer sales channels will provide the foundation for the success of Mota. Combined total sales of almost $29,000,000 with a EBITDA of approximately 12.5% (2019) . Click Here for More Info

Mota large

CBD oil is increasingly acclaimed for its benefits. Use as an e-liquid for vaping, but also as a dietary supplement to fight against stress or depression, CBD is everywhere.

Find out what its benefits are, how to consume it, and where to find it.

With some of the best online suppliers in Europe, British users can now easily find and order CBD flowers in UK. It has simplified the way to purchase high-quality CBD online, and we can now enjoy the best CBD oils.

What is CBD oil?

CBD, or cannabidiol, is part of the family of cannabinoids, a group of molecules found in the hemp plant, such as THC or CBD. We all have so-called cannabinoid receptors in our brains, which explains why these compounds have a more or less significant impact on the human nervous system.

CBD oil is extracted from the cannabis plant. It contains mostly cannabidiol, the concentration of which varies depending on the product. Today it is mainly used as an e-liquid for electronic cigarettes, as CBD oil to add in food and drinks, and CBD capsules.

While the hemp plant has been cultivated for over 6.000 years in China, it is only today that CBD oil is becoming more and more popular, as scientists discover many benefits for our organism. Indeed, unlike THC, another cannabinoid, CBD does not have psychotropic properties. For this reason, cannabidiol is also called “therapeutic cannabis”!

What are the effects of CBD oil?

Unlike THC, the effects of CBD oil are not harmful to our nervous system. CBD does not cause a feeling of intoxication or euphoria, unlike THC, and therefore no loss of control.

Conversely, it offers a feeling of serenity and a sense of relaxation. CBD is also found in recognized drugs like Cannador, Sativex, or Epidiolex.

To start with, CBD oil can help you fall asleep. If it does not have the effect of a sleeping pill, it will, however, cause your body to relax to promote falling asleep indirectly.

Likewise, CBD oil can help you not only to combat stress but also to regulate your mood. Indeed, CBD acts in particular on receptors linked to anxiety. For this reason, it is reputed to be a powerful anxiolytic and is effective in treating depression.

Note that paradoxically, CBD oil can help you fight against drug addiction since it will promote emotional balance while helping you overcome anxiety and stress, often overwhelming during withdrawal.

Finally, CBD oil can be used as an anti-inflammatory, especially in the case of Crohn’s disease, a chronic inflammatory disease of the digestive system.

How should you use CBD oil?

CBD oil is consumed orally, by placing 1 to 2 drops on your tongue or by adding them to your food or drink. The bottles sold are therefore often equipped with a pipette. After swallowing the CBD oil drops, leave it on for 30 seconds before continuing to eat or keep busy.

Please note, it is essential not to exceed 3 doses per day. If you take too much CBD oil, you risk increasing the relaxing effects and wanting to sleep! The ideal is to start with a low dosage and increase it gradually if you support it.

Also, CBD oil is not recommended for pregnant women.

Is CBD oil legal in the UK?

Cannabis derivatives do not have an outstanding reputation, in particular, because of THC, the compound which has psychotropic effects. European legislation is therefore relatively strict with cannabidiol. For example, any product containing THC is prohibited if the THC level exceeds 0.2 %.

However, products from Cannabis sativa seeds and stems are not prohibited in the UK, which explains why most of the CBD oils currently on sale come from them. Despite everything, CBD oil remains banned for minors. No law has been enacted regarding CBD oil, but case law prevails until European law issues an opinion on the subject, not always in a pleasant manner!

Where to buy CBD oil?

CBD-based products are very numerous: crystals (the purest form) for culinary preparations or other uses of this type, oil, e-liquid for electronic cigarettes, CBD flowers, CBD resins, etc. You will, therefore, have no harm to find CBD for your consumption.

On the Internet, you will mainly find CBD oil, as on the online store. You will find a whole lot of websites that are claiming to sell the best CBD products. However, you should only buy the best quality of CBD flowers and CBD oils.

Check websites such as Justbob.shop to find the right CBD products. As a leading company in Europe, this supplier from Italy is offering natural CBD flowers and great CBD oils. Also, they are following a set of many quality controls, and they are recognized by the Italian authorities, which means that they are well-known and that they are complying with local and European laws.

Source: London Loves Business

https://londonlovesbusiness.com/discovering-the-benefits-of-cbd-oil/

Tags: , , , , , , , , , ,
Posted in All Recent Posts, Mota Ventures Corp. | Comments Off on Discovering the Benefits of CBD Oil SPONSOR: Mota Ventures $MOTA.ca $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

MUST WATCH INTERVIEW OF THE YEAR – Empower Clinics $CBDT.ca Closes Up 77% On 25M Shares. This Is Why … And This Is Where It Is Going $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 9:47 PM on Monday, April 27th, 2020

With 165,000 patients, Empower Clinics (CBDT:CSE) (EPWCF:OTCQB) has a database that almost every medical cannabis and CBD company would kill for.  Patient visits increased 800% in February. 590% in March and 480% for Q1. 

More importantly, it is the only small cap company on the continent (that we know of) that is capable of launching COVID-19 Antibody Testing for individuals and businesses nationwide.  Why?  Because its simply not enough to be able to get your hands on some test kits.  The real challenge is having the infrastructure in place to test people in clinics, via drive though and in the workplace.    

It’s pretty much a military precision process that few small cap CEO’s could handle.  

But Empower Clinics CEO, Steven McAuley, is Six Sigma certified under the quality initiative of legendary GE (General Electric) Chairman Jack Welch. We’ve never seen a Six Sigma certified CEO in the Canadian small cap markets. Never …. which explains how McAuley has been able to guide Empower Clinics through the most disruptive retail environment in recent history and turn it into significant growth.  

And now he’s set his sights on Antibody Testing.  He’s not just looking, he’s already started.  

Forget NetFlix Tonight.  Watch this.

Tags: , , , , ,
Posted in AGORACOM Via Satellite, Empower Clinics Inc., Featured | Comments Off on MUST WATCH INTERVIEW OF THE YEAR – Empower Clinics $CBDT.ca Closes Up 77% On 25M Shares. This Is Why … And This Is Where It Is Going $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca

« Older Entries
Newer Entries »